Genetic analysis of N6-methyladenosine modification genes in Parkinson's disease

Lixia Qin,Shishi Min,Li Shu,Hongxu Pan,Junfei Zhong,Jifeng Guo,Qiying Sun,Xinxiang Yan,Chao Chen,Beisha Tang,Qian Xu

DOI: https://doi.org/10.1016/j.neurobiolaging.2020.03.018

IF: 5.133

2020-09-01

Neurobiology of Aging

Abstract:<p>Parkinson's disease (PD) is a common neurodegenerative disease with a relatively unclear etiology. Previous studies have shown that N6-Methyladenosine (m6A) is a vital RNA modification enriched in brain tissue, and that the genes involved in m6A-modification are implicated in various neurological diseases. Here, we conducted a comprehensive genetic analysis using targeted sequencing with molecular inversion probes (MIPs) to identify m6A-modification genes (including <em>METTL3, METTL14, WTAP, FTO, ALKBH5, YTHDF1, YTHDF2, YTHDF3, HNRNPC</em> and <em>ELAVL1</em>) in a total of 1,647 sporadic PD patients and 1,372 controls of Han Chinese origin. PD patients were divided into early-onset PD (EOPD) and late-onset PD (LOPD) based on whether the onset of motor symptoms occurred before or after 50 years of age. Rare variants were subjected to gene-based burden tests and common variants were subjected to single-variant association analyses. As a result, we identified 214 rare variants in all 10 m6A-modification genes and 16 common variants in 7 genes. Gene-wise association analyses of rare variants in each m6A-modification gene did not achieved a <em>p</em> value of less than 0.05 in either total cohorts or two age groups. In fact, <em>p</em> values greater than 0.05 were found when conducting single-variant association analyses on common variants of these genes between PD and control patients. Our comprehensive analyses of m6A modification genes suggest that there is no significant association between these 10 m6A-modification genes and the risk of sporadic PD.</p>

neurosciences,geriatrics & gerontology,gerontology